CBD Global Sciences Inc. (CSE:CBDN)

Get Top Rated Stock Alerts Active Traders Depend On

Sign Up Today For FREE News Driven Alerts

CBD Global Sciences Reports Q3 2019 Results with Revenue of $1.79 million up over 1,000% from Q3 2018 Revenue of $144,000

Denver, CO – December 5, 2019 – CBD Global Sciences, Inc. (CSE: CBDN) (Frankfurt:GS3), “CBD Global” or the “Company”), today announced the release of financial and operational results for the third quarter ended September 30, 2019. These filings are available for review on the Company’s SEDAR profile at www.sedar.com. All amounts are expressed in U.S. dollars.

Financial Highlights

For the nine months ended September 30, 2019 revenue growth of 800% increase to $4.9 million from $600,000 revenue in all of fiscal 2018.
The increase is attributed to a larger crop size, more effective farming methods, and the harvesting of plants for smokable and pre-rolled products.
A larger variety of products sold in 2019 versus 2018.
Addition of CBD products, smokable bud and clones sold in 2019.
A larger crop harvest in 2018 (sold in 2019) versus crop harvest in 2017 (sold in 2018).
The 2019 crop is larger and more potent than 2018.

Gross Profit (before fair value adjustments) increased to 74% in 2019 from 4.9% in 2018. This was a direct result of increase in the sales price per pound with the addition of smokable CBD products and increase consumer demand.

Assets and inventory:
Larger amounts of biomass were harvested per plant in 2019 versus in 2018.
Potency of CBD per plant continues to increase year over year.
The higher the potency of the plant generally will lead to more efficient processing of the plant into CBD oil, which may translate to a higher plant value.
A small increase in cost of production per plant of $2.62 in 2019 versus $2.42 in 2018, due to a larger labor base.

Third Quarter 2019 Business Highlights:

The Aethics brand products have expanded into new States and locations with current and new retail partners which includes 248 news doors.
Reorders are already coming in which presents strong sell through with the selected products.
Increased product depth with new CBD performance drops, hydration drinks, and lotions.

“In an increasingly crowded and confusing CBD market, brands matter, and CBD Global continues to be a trusted provider of high-quality CBD product,” said Brad Wyatt, CEO of CBD Global Sciences. “Consumers are becoming more informed on choices of product in the CBD market space and are directing their purchases to the highest quality product and best value proposition.”

ABOUT CBD GLOBAL SCIENCES INC.

CBD Global Sciences, Inc., is a vertically integrated hemp-based CBD producer, extractor, and branding investment vehicle which currently owns two product categories, branded under the name AETHICS (www.aethics.com) and CANNAOIL (www.cannaoilshop.com), which include CBD Oil tinctures (liquid products), CBD capsules, CBD topicals. CBD Global Sciences hemp-derived CBD extracts are sold through select distributors, brick and mortar retailers, and online.

CBD Global Sciences, through its wholly owned subsidiary, Strasburg Pharms, grows and operates irrigated land in Colorado, that grows hemp with only all-natural Colorado water, soil, sun and nutrients and NEVER sprayed with pesticides or chemicals. Our genetics are hand selected and maintained to present the best cannabinoid profile with extremely high CBD. The extraction/processing facility, operated by CBD Global Sciences, is located approximately 40 minutes from the farm.

For further information, please contact Bruce Nurse, Investor Relations, (888) 401-2239, info@cbdglobalsciences.com

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAS REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION: This news release includes certain “forward-looking statements” under applicable Canadian securities legislation. Forward-looking statements include, but are not limited to, statements with respect to future developments and the business and operations of the Corporation after the CSE listing. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to general business, economic, competitive, political and social uncertainties; and delay or failure to receive board, shareholder or regulatory approvals. Readers should not place undue reliance on forward-looking statements. The Corporation disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

NOT FOR DISTRIBUTION OR DISSEMINATION INTO THE UNITED STATES

Source: CBD Global Sciences, Inc.

CBD Global Sciences Achieves Listing on The Frankfurt Stock Exchange

Denver, CO – November 25, 2019 – CBD Global Sciences, Inc. (CSE: CBDN) (“CBD Global” or the “Company”), today announced that its common shares have been listed on the Frankfurt Stock Exchange under the symbol “GS3.” The Company’s common shares continue to be listed on the Canadian Securities Exchange under the symbol “CBDN.”

Brad Wyatt, CEO of the Company, commented, “We are excited to provide shareholders of CBD Global additional market access in order to increase the continuing liquidity of CBD Global stock. We are also excited to enter the European marketplace as an access point for European investors in the ongoing CBD Global success story.”

ABOUT CBD GLOBAL SCIENCES INC.

For further information, please contact Bruce Nurse, Investor Relations, (888) 401-2239, info@cbdglobalsciences.com

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAS REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Source: CBD Global Sciences, Inc.

CBD Global Sciences Announces Expansion of Aethics Hydration Product Line

Denver, CO – November 19, 2019 – CBD Global Sciences, Inc. (CSE: CBDN) (“CBD Global” or the “Company”) is pleased to announce the expansion of its Aethics Hydration product line, launching an all new lineup comprised of infused CBD Balance Sparkling Water in 3 flavors – Grapefruit, Berry, and Lemon Lime. With today’s launch of the expanded Aethics Hydration product line, CBD Global’s aim is to increase its market share in the rapidly growing market segment for hemp-derived CBD sports water.

CBD-infused beverages are considered to be the fastest growing segment in the overall market. According to market research firm, Zenith Global (https://www.zenithglobal.com/about_us), the U.S. cannabis-infused drinks market will reach an estimated $1.4 Billion by 2023.

CBD Global’s water line can be viewed and purchased online at https://aethics.com/products/cbd-sparkling-water-for-athletes-by-aethics-h20-balance, and is available through retail outlets nationwide.

The Company’s Sparkling Water is a 12-ounce can infuse with 10mg of CBD and flavor extract. The H2O Balance Sparkling water uses a refined full-spectrum formulation to preserve the full range of the hemp-plant’s beneficial components.

Brad Wyatt, CEO & President, states ” Our company continues to demonstrate its ability to be timely and innovative in creating multiple varieties for our hydration lines that will enhance the consumer’s ability to find a product that they will enjoy as a refreshing way to rehydrate with a full spectrum compliment of CBD and other supportive cannabinoids.”

ABOUT CBD GLOBAL SCIENCES INC.

For further information, please contact Bruce Nurse, Investor Relations, (888) 401-2239, info@cbdglobalsciences.com

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAS REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Source: CBD Global Sciences, Inc.

About CBDN

About CBD Global Sciences

Empowering people globally for a healthier way of living.

CBD Global Sciences is an American multi-national consumer goods and farming company headquartered in Denver, Colorado, founded by American entrepreneurs Brad Wyatt and Glenn Dooley. It specializes in a wide range of CBD products and the cultivation of hemp plants.

In 2015, co-founders Brad and Glenn recognized the growing demand for hemp and quickly became one of the leading hemp-farming companies in Colorado. The Company’s President and CEO, Brad Wyatt, said, “the future of Cannabidiol products start from the seed and it doesn’t end for us until we’ve packaged the product to sell.”

Today, we are working to build a growing and profitable company. Our goal is clear—meeting the needs of consumers better than our competitors to deliver shareholder value. We are doing this by concentrating on developing a strong leadership team, leading in innovative Cannabidiol (CBD) products, ensuring ethical quality management and control, creating protective legal and regulatory guidelines globally, setting new standards of quality, bringing a productivity mindset, and inspiring our people to keep the consumer at the center of everything we do.

Growth through innovation.

Delivering the education of Cannibidiol and it's incredible benefits is what we set out to do for all people globally. Our vision is clear—meeting the needs of consumers better than our competitors to deliver shareholder value. We are doing this by concentrating on developing a strong leadership team, leading in innovative Cannabidiol (CBD) products, ensuring ethical quality management and control, creating protective legal and regulatory guidelines globally, setting new standards of quality, bringing a productivity mindset, and inspiring our team to keep the consumer at the center of everything we do. As a company we strive to create innovative ways to push the envelope with new, cutting-edge CBD products.

Brad Wyatt
CEO

Services

Given its explosion over the last few years, it seems like everyone is trying to get into CBD. Unfortunately, this has led to the rise of countless companies offering products and services that are not what they claim to be – some even going as far as selling oil that has no CBD in it at all. CBD Global Sciences is not one of these companies. Below are some of the services we provide and the details you need to know to get started.

Our Farm

At our farm in Strasburg, Colorado, we produce 100% organically grown hemp on over 500 acres. Due to generations of carefully picked genetics, we are able produce a rich, full-spectrum plant that maximizes CBD potency and terpene profile while keeping THC at or below .3%. During growth we never use any chemicals or pesticides and our plants are always cultivated with an all-natural and sustainable approach that has been shown to save over 80% of the water we use. Our farm is licensed and regulated by the Department of Agriculture and our growing process exceeds all state and federal organic growing requirements.

Our Lab

Our Lab Located minutes from the farm, our hemp travels to our 20,000 sft state-of-the-art lab to be processed. Using a proprietary cold fusion, ethanol-extraction process, we are able to lock in the vital terpenes and cannabinoids which are then removed from the plant itself. As well as being the most efficient and therefore least wasteful approach, this is also one of the most natural and effective ways to produce oil, and as a result, our final product is one of the finest in the world.

Our Oil

Our Oil As a result of our exceptional practices and processes, we can produce an ultra-high-quality, full-spectrum CBD oil that we are extremely proud of. In third party testing, our oil is shown not only to be contaminant and microbial free, but also outstanding in its potency and purity. We trust that you and your customers will love our oil as much as we do.

PRIVATE LABEL

At CBD Global Sciences, our measure of success is different than many of our competitors. While others rabidly pursue higher revenues or greater brand recognition, our goal is to share the health-enhancing benefits of CBD with as many people as possible. In order to maximize this effort, we believe it is fundamentally important to share our resources with similarly motivated and passionate people. This why we created the Private Label Program. With this program we aim to provide current and future companies with the finished products they need to begin selling CBD right away.

WHOLESALE

CBD Global Sciences is a proud provider of natural-hemp-extracted CBD products grown organically in Colorado. We offer a wide variety of quality, wholesale bulk CBD products. Our organic growing process surpasses our competitors. Simply choose the items you want to receive discounted bulk pricing. Click below for more information.

Source: https://www.cbdglobalsciences.com/

Disclaimer

FN Media Group LLC (FNMG) owns and operates FinancialNewsMedia.com (FNM) which is a third party publisher that disseminates electronic information through multiple online media channels. FNMG’s intended purposes are to deliver market updates and news alerts issued from private and publicly trading companies as well as providing coverage and increased awareness for companies that issue press to the public via online newswires. FNMG and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. The companies that are discussed in this release may or may not have approved the statements made in this release. Information in this release is derived from a variety of sources that may or may not include the referenced company’s publicly disseminated information. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. While this information is believed to be reliable, such reliability cannot be guaranteed. FNMG disclaims any and all liability as to the completeness or accuracy of the information contained and any omissions of material fact in this release. This release may contain technical inaccuracies or typographical errors. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. Investment in the securities of the companies discussed in this release is highly speculative and carries a high degree of risk. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. This release is not without bias, and is considered a conflict of interest if compensation has been received by FNMG for its dissemination. To comply with Section 17(b) of the Securities Act of 1933, FNMG shall always disclose any compensation it has received, or expects to receive in the future, for the dissemination of the information found herein on behalf of one or more of the companies mentioned in this release. For current services performed FNMG has been compensated thirty five hundred dollars for CBD Global Sciences Inc. current news coverage by a non-affiliated third party. FNMG HOLDS NO SHARES OF CBD Global Sciences Inc.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.